The upcoming FDA panel evaluating the risks associated with long term bisphosphonate use could be rittled with conflicts of interest Pharmalot reports. The join panel consists of the FDA's Drug Safety and Risk Management Advisory Committee and the FDA's Reproductive Health Drugs Advisory Commitee. When Pharmalot looked further into the individual member's backgrounds, they found that a number of them had ties to drug companies that manufacture bisphosphonates, such as Fosamax, Boniva, Actonel, Atelvia, and Reclast.
The FDA has not issued any conflict of interest waivers to the members of the joint panel, however there are at least four members that have received money from either Merck (Fosamax), Roche (Boniva), Warner-Chillcott (Actonel and Atelvia), or Novartis (Reclast).
The results of the panel could mean that bisphosphonates have yet another label change. The last label change was recommended less than a year ago after the American Bone and Mineral Research Soceity issued a report linking bisphosphonates to atypical thigh bone fractures.
Our firm filed one of the first femur fracture cases in 2009 and is deeply involved in the Femur Fracture litigation in Atlantic County New Jersey.
